Aardvark Therapeutics, Inc. Common Stock
AARD
Rank in Stocks
#24206
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical... Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Share Price
$1.59
Last synced: 2026-11-11
Market Cap
$34.74M
Change (1 day)
16.06%
Change (1 year)
-85.36%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Aardvark Therapeutics, Inc. Common Stock (AARD)
Category
Healthcare
EPS for Aardvark Therapeutics, Inc. Common Stock (AARD)
EPS as of June 2026 TTM: $-3.21
According to Aardvark Therapeutics, Inc. Common Stock's latest financial reports, its current EPS (TTM) is $-3.21. At the end of 2025 the company had an EPS of $-2.64, a decrease compared to its 2024 EPS of $-0.95.
EPS history for Aardvark Therapeutics, Inc. Common Stock from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.21 | 21.59% |
| 2025 | $-2.64 | 177.89% |
| 2024 | $-0.95 | 179.41% |
| 2023 | $-0.34 | -46.03% |
| 2022 | $-0.63 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -587.85% |
US
|
|
| $-7.07 | 120.25% |
US
|
|
| $-5.29 | 64.80% |
AU
|
|
| $12.88 | -501.25% |
BE
|
|
| $21.56 | -771.65% |
NL
|
Questions about Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS)
What is Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS)?
Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS) over the last twelve months is $-3.21, as of Jun 2026.
What was Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS) in 2025?
In 2025, Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS) was $-2.64, compared with $-0.95 in 2024.
How has Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS) changed since 2022?
From 2022 to 2025, Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS) was highest in 2023 ($-0.34) and lowest in 2025 ($-2.64).
How does Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS) compare with similar companies?
Aardvark Therapeutics, Inc. Common Stock's earnings per share (EPS) ($-3.21) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.